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N = 5415
Eligible women at follow-up
Respondents (baseline & follow-up)
N = 4093 Women older than 44 years at follow-up
Women without non-menopause related menstrual irregularityN = 3883
Women not taking exogenous hormonesN = 2568
Women with complete information on BMI and smokingN = 2539
N = 2322 Population for current study
n = 1322 (Younger than 45 years at follow-up)
n = 210 (Pregnancy [86], breastfeeding [1], PCOS [86], constant irregular menstruation [37])
n = 1315 (Contraception [557], hormone replacement therapy [631], other reasons [127])
n = 29 (Incomplete information on BMI [5] or smoking [24])
n = 217 (Asthma before / at baseline)
N = 8588
n = 3173 (Non respondents, response rate 63%)
Eligible women at baselineN = 11153
n = 2565 (Non-respondents, response rate 77%)
FIG 1. Study population with inclusion and exclusion criteria.
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TRIEBNER ET AL 511.06-4.20), and late postmenopausal (odds ratio, 3.44; 95% CI,
1.31-9.05) at follow-up compared with nonmenopausal women.
The risk of respiratory symptoms increased in early
postmenopausal (coefficient, 0.40; 95% CI, 0.06-0.75) and late
postmenopausal (coefficient, 0.69; 95% CI, 0.15-1.23) women.
These findings were consistent irrespective of smoking status
and across study centers.
Conclusions: New-onset asthma and respiratory symptoms
increased in women becoming postmenopausal in a longitudinal
population-based study. Clinicians should be aware that
respiratory health might deteriorate in women during
reproductive aging. (J Allergy Clin Immunol 2016;137:50-7.)
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Since Aristotle’s time, menopause has been known to occur
around 50 years of age.1,2 However, most women did not live to
experience menopause in earlier days. In the last decades, female
life expectancy has increased beyond 50 years worldwide,3 and
today, the implications of menopause for health and disease are
highly relevant.Menopause is associatedwith profound hormonal
and metabolic changes: estrogen levels are low after menopause,
and features of the metabolic syndrome become more prevalent
paired with increasing risk of chronic conditions, such as diabetes
and cardiovascular diseases.4 However, our understanding of po-
tential changes of asthma and respiratory health in relation to
menopause is still very limited, despite an increasing awareness
of the importance of reproductive and hormonal factors in asth-
matic patients.5-8 It has been suggested that late-onset asthma
can be triggered by a change in systemic inflammation9,10 as it
happens (ie, with menopause). Airways inflammation in post-
menopausal asthmatic patients seems to be different from that
of patients with earlier-onset asthma, as characterized by poorer
response to anti-inflammatory treatment, as well as more frequent
and severe exacerbations.10
Large epidemiologic studies investigating menopause and
asthma are scarce and show contradictory results.11 A lower
risk of asthma among postmenopausal compared with nonmeno-
pausal nurses was found in women who had never used hormone
replacement therapy (HRT).12 In contrast, a cross-sectional
population-based study of women aged 45 to 55 years and not
currently using HRT found more asthma and respiratory
symptoms and lower lung function in women who had stopped
menstruating compared with those who still had regular
menstruations.13 Furthermore, an association between impaired
respiratory health and menopause has been suggested by studies
in which womenwho underwent surgical menopause had a higher
risk of wheeze, independent of previous use of HRT,14 and that
postmenopausal status was associated with increased risk of
respiratory symptoms.15
Research in this field has generally focused on HRT, whereas
the underlying condition, namely menopause, has usually not
been adequately studied because of the lack of sufficiently
detailed information on menstrual patterns and statistical power
to conduct the necessary subgroup analyses.5 An effect of
menopause itself is plausible given that sex differences appear
to play a major role in the development of respiratory health as
a result of male and female sex hormones acting differently on
resident lung cells and immune function.16The Respiratory Health in Northern Europe17 women’s study
included longitudinal data on reproductive and respiratory
health from large general population samples (n 5 5415) with a
median age of 40 years at baseline and 51 years at follow-up.
This provides an extraordinary opportunity to longitudinally
study the natural history of asthma and respiratory symptoms
during reproductive aging. In the present study we aimed to
investigate new-onset asthma and change in respiratory
symptoms in relation to change in menopausal status over a
12-year period.METHODS
Study population
Respiratory Health in Northern Europe is an international, multicenter,
longitudinal study (www.rhine.nu) that included 7 Northern European centers
(Bergen in Norway, Reykjavik in Iceland, Umea, Uppsala and Gothenburg in
Sweden, Aarhus in Denmark, and Tartu in Estonia). At baseline (1999-2001),
a respiratory health–focused postal questionnaire was sent to eligible
participants (nwomen 5 11,153), 77% (nwomen 5 8,588) of whom responded.
The questionnaire included questions concerning menstruation, menopause,
and hormone use. At follow-up (2010-2012) 12 years later, 2 separate postal
questionnaires, one focused on lung health, background characteristics, and
risk factors and another focused on women’s health, were sent to all female
participants. The response rate for returning both questionnaires was 63%
(nwomen 5 5,415).
TABLE I. Characteristics of the study population by change in menopausal status
All Nonmenopausal* Menopausal transitiony Early postmenopausez Late postmenopause§
Age (y), median (SD) 54.0 (5.5) 48.0 (3.0) 52.0 (4.4) 55.0 (4.8) 62.0 (3.0)
BMI (kg/m2), median (SD) 24.7 (4.5) 24.2 (4.3) 24.4 (4.5) 24.8 (4.4) 25.4 (5.0)
Smoking
Never smoker 1090 (46.9) 235 (54) 150 (51.5) 594 (44) 111 (45.1)
Former smoker 829 (35.7) 138 (31.7) 100 (34.4) 512 (37.9) 79 (32.1)
Current smoker 403 (17.4) 62 (14.3) 41 (14.1) 244 (18.1) 56 (22.8)
Physical activityk
>1 h/wk (vigorous) 895 (38.5) 201 (46.2) 128 (44) 498 (36.9) 68 (27.6)
>1 h/wk (light) 458 (19.7) 58 (13.3) 50 (17.2) 281 (20.8) 69 (28)
<1 h/wk (vigorous) 268 (11.5) 67 (15.4) 39 (13.4) 145 (10.7) 17 (6.9)
<1 h/wk (light) 325 (14) 52 (12) 41 (14.1) 192 (14.2) 40 (16.3)
None 376 (16.2) 57 (13.1) 33 (11.3) 234 (17.3) 52 (21.1)
Education
University 1112 (47.9) 255 (58.6) 162 (55.7) 617 (45.7) 78 (31.7)
Secondary 960 (41.3) 163 (37.5) 112 (38.5) 580 (43) 105 (42.7)
Primary 250 (10.8) 17 (3.9) 17 (5.8) 153 (11.3) 63 (25.6)
Symptoms{
Breathless while wheezing 182 (7.8) 24 (5.5) 23 (7.9) 111 (8.2) 24 (9.8)
Woken by chest tightness 211 (9.1) 38 (8.7) 23 (7.9) 125 (9.3) 25 (10.2)
Woken by shortness of breath 113 (4.9) 20 (4.6) 8 (2.7) 72 (5.3) 13 (5.3)
Asthma{
Asthma attack 56 (2.4) 3 (0.7) 9 (3.1) 35 (2.6) 9 (3.7)
Asthma medication 99 (4.3) 11 (2.5) 14 (4.8) 60 (4.4) 14 (5.7)
New-onset asthma# 109 (4.7) 12 (2.8) 16 (5.5) 64 (4.7) 17 (6.9)
Total 2322 435 291 1,350 246
Values are presented as numbers (percentages), unless otherwise stated.
*Regular menstruation at baseline and follow-up.
Regular menstruation at baseline and irregular or few menstruations at follow-up (irregular for a few months, 3-9 periods in the last 12 months, no menstruation for <6 months, 1
ovary removed or hysterectomy).
Regular menstruation at baseline and postmenopause at follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
§Postmenopause at baseline and follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
kExercise frequency per week * duration per session for either light or heavy intensity (frequency per week * duration 5 numbers of training units per week times their duration
[unit: h/wk]).
{In the last 12 months.
#Current use of asthma medication, asthma attack, or both during the last 12 months in 2010 and no asthma at baseline.
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women using exogenous hormones, women who were pregnant or
breast-feeding at the time of the survey, women reporting persistent irregular
menstruation, and women with polycystic ovary syndrome according to the
Rotterdam criteria.18 Women defined as having asthma at baseline (current
asthma medication use, asthma attack during the previous 12 months, or
both) and/or ever having had asthma (n 5 217) were excluded. The study
population thus consisted of 2322 women aged more than 44 years at
follow-up with complete data (Fig 1). Characteristics of the study population
by center can be found in Table E1 in this article’s Online Repository at www.
jacionline.org. Ethical approval was obtained for each study center from the
appropriate institutional or regional ethics committee, and each participant
provided informed written consent.
Outcomes
New-onset asthma was defined as current asthma medication use, having
had an asthma attack during the last 12 months, or both. A respiratory
symptoms score ranging from 0 to 3 was created according to existing
literature,19,20 adding the numbers of affirmative answers to the following 3
questions: ‘‘Have you been breathless while wheezing at any time in the last
12 months?,’’ ‘‘Have you woken up with a feeling of tightness in your chest
at any time in the last 12 months?,’’ or ‘‘Have you been woken by an attack
of shortness of breath at any time in the last 12 months?’’
Menopausal status
Menopausal status was defined based on criteria of the Stages of
Reproductive Aging Workshop (STRAW) clinically oriented classification,21with the exception that a cutoff of 6 months or more of amenorrhea was used
instead of 12 months or more because of the definition of menopause in
the questionnaire at baseline. The questions used to define menopausal status
at baseline and at follow-up are presented in the Methods section in this
article’s Online Repository at www.jacionline.org. On the basis ofmenopausal
status at baseline and follow-up, we defined change in menopausal status as
follows:
1. nonmenopausal: nonmenopausal at both baseline and follow-up
(reference category);
2. transitional: nonmenopausal at baseline and transitional at follow-up;
3. early postmenopausal: nonmenopausal at baseline and menopausal at
follow-up; and
4. late postmenopausal: menopausal at both baseline and follow-up.Measurements of estradiol levels in serum
In a subsample of the study population (n5 323), serum estradiol levels at
follow-up were measured at the Core Facility for Metabolomics, University of
Bergen (www.uib.no/metabolomics) by using liquid chromatography–tandem
mass spectrometry. Estradiol concentrations were used to define
premenopausal and postmenopausal status according to an established cutoff
of 73 pmol/L.22Covariates
Self-reported height and weight at follow-up were used to calculate body
mass index (BMI [in kilograms per meters squared]). Weight at follow-up was
J ALLERGY CLIN IMMUNOL
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the average change of the study population’s BMI from baseline to follow-up
to their baseline BMI. Smoking was categorized according to whether
participants were never, current, or former smokers at baseline and
follow-up. Age reported at follow-up was used for adjustment. For cases
with missing data on age at follow-up (n5 140), we added years of follow-up
for each participant to reported age at baseline. Physical activity was stratified
into 5 groups based on information on frequency, intensity, and duration of
exercise reported at follow-up (Russell et al, unpublished data). The following
3 levels of education were reported: university or college, secondary or
technical school, and primary school.Statistical analysis
Logistic regression models were used to analyze the association of change
in menopausal status with development of new-onset asthma. Negative
binomial regression models suited for high-dispersion data were used to
analyze the association of change in menopausal status with change in the
respiratory symptoms score. The final regression models were adjusted by age
and BMI as continuous variables and smoking, physical activity, education,
and study center as categorical variables. Sensitivity analyses were performed
in never smokers and women who did not have new-onset asthma. Analyses
were stratified by BMI in tertiles, and analysis of interaction by center and
BMI were performed by introducing an interaction term. All analyses
were performed with STATA software (Version 13; StataCorp, College
Station, Tex).FIG 2. New-onset asthma according to change in menopausal status
(n 5 2322). The size of each circle is proportional to the number of persons
in each group.RESULTS
At follow-up, 19% of the women were nonmenopausal, 13%
were transitional, 58%were early postmenopausal, and 11%were
late postmenopausal. The median age of the study population was
54 years (s 5 5.5 years), the median age at menopause was
50.2 years (s 5 5.7 years), and mean BMI was 24.7 kg/m2
(s 5 4.5 kg/m2). The average number of respiratory symptoms
was 0.2 (range, 0-3), and there were 109 (5%) cases of
new-onset asthma (Table I).
Both women in the menopausal transition and postmenopause
were older, heavier, more often current or former smokers, less
well educated, and exercised less than nonmenopausal women
(Table I).
Among women categorized as nonmenopausal according to
questionnaire data, 84% had estradiol levels of 73 pmol/L or
greater. Among women categorized as postmenopausal, 78% had
estradiol levels of less than 73 pmol/L.
The risk for new-onset asthma was higher for women in the
menopausal transition or who were postmenopausal compared
with nonmenopausal women who had regular menstruation
throughout the study period (Fig 2 and Table II). Age was not
an independent predictor for new-onset asthma, and adjustment
for age did not alter the association with menopause. Women
who became transitional or menopausal during the follow-up
period had more than double the risk of new-onset asthma, and
women who were postmenopausal at baseline had more than
triple the risk of new-onset asthma at follow-up compared with
nonmenopausal women.
Womenwhowere in early and late postmenopause at follow-up
had a significant increase in the number of respiratory symptoms
compared with women who remained nonmenopausal (Fig 3 and
Table III). This effect was not driven by women who had
new-onset asthma as a sensitivity analysis; excluding these
women showed similar results (see Table E2 in this article’s
Online Repository at www.jacionline.org).There was no significant interaction between study center and
menopausal status in the associations with new-onset asthma
(Pheterogeneity5 .14) or respiratory symptoms (Pheterogeneity5 .78).
Stratification by smoking showed similar results in never, former,
and current smokers for both outcomes (see Tables E3 and E4 in
this article’s Online Repository at www.jacionline.org). Analysis
of effect modification by BMI showed that the effects of
menopause on new-onset asthma were stronger for those with
higher BMI (continuous variable; Pinteraction 5 .054 for
interaction with early postmenopause; Pinteraction 5 .047 for
interaction with late postmenopause; see Table E5 in this article’s
Online Repository at www.jacionline.org).DISCUSSION
This study showed that the risk of new-onset asthma was
significantly higher in women who were transitional or
postmenopausal at follow-up compared with women who were
nonmenopausal at baseline and follow-up. Furthermore, the
number of respiratory symptoms was higher in women who
TABLE II. New-onset asthma according to change in menopausal status and covariates (n 5 2322)
Percent (no./N)
Unadjusted Adjusted
OR (95% CI) P value OR (95% CI)* P value
Menopausal status
Nonmenopausal 2.8 (12/435) Reference Reference
Menopausal transition 5.5 (16/291) 2.05 (0.96-4.40) .07 2.40 (1.09-5.30) .03
Early postmenopause§ 4.7 (64/1350) 1.75 (0.94-3.28) .08 2.11 (1.06-4.20) .03
Late postmenopausek 6.9 (17/246) 2.62 (1.23-5.57) .01 3.44 (1.31-9.05) .01
Age 1.00 (0.96-1.03) 1.0 0.97 (0.92-1.01) .2
BMI 1.06 (1.02-1.09) .004 1.06 (1.02-1.10) .003
Smoking
Never smoker Reference Reference
Former smoker 1.44 (0.92-2.26) .11 1.35 (0.85-2.14) .2
Current smoker 2.23 (1.36-3.65) .001 1.92 (1.15-3.22) .01
Physical activity{
>1 h/wk (vigorous) Reference Reference
>1 h/wk (light) 0.82 (0.47-1.41) .5 0.82 (0.47-1.44) .5
<1 h/wk (vigorous) 0.51 (0.23-1.14) .10 0.49 (0.22-1.11) .09
<1 h/wk (light) 0.79 (0.42-1.48) .5 0.70 (0.36-1.36) .3
None 1.35 (0.81-2.23) .2 1.11 (0.65-1.90) .7
Education
University Reference Reference
High school 0.97 (0.64-1.48) .9 0.81 (0.53-1.26) .4
Primary 1.55 (0.88-2.74) .13 1.21 (0.65-2.26) .5
Boldface indicates estimates with a P value less than .05 (statistical significance).
OR, Odds ratio.
*Logistic regressions mutually adjusted for all covariates.
Regular menstruation at baseline and follow-up.
Regular menstruation at baseline and irregular or few menstruations at follow-up (irregular for a few months, 3-9 periods in the last 12 months, no menstruation for <6 months,
1 ovary removed or hysterectomy).
§Regular menstruation at baseline and postmenopause at follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
kPostmenopause at baseline and follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
{Exercise frequency per week * duration per session for either light or heavy intensity (frequency per week * duration 5 numbers of training units per week times their duration
[unit: h/wk]).
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who were nonasthmatic at baseline and had not had asthma
previously. The findings remained consistent after adjustment for
age, BMI, and lifestyle factors. Age was not an independent
predictor of new-onset asthma in the studied age span, and the
findings could not be attributed to general aging. Sensitivity
analyses in never smokers showed similar results, and findings
were consistent across study centers. There was significant effect
modification by BMI because the association of new-onset
asthma with menopause was significantly stronger with higher
BMI.
To our knowledge, this is the first longitudinal
population-based study that addresses respiratory health in
relation to menopause. Previous cross-sectional analyses
show results that agree with the present longitudinal analysis,
with higher prevalence of asthma, respiratory symptoms, or
both in postmenopausal compared with nonmenopausal
women.13-15
A negative association between menopause and asthma risk
was reported in an analysis of the Nurses’ Health Study.12
Differences in study populations and in definition of exposure
and outcome might explain the discordant results; furthermore,
North American nurses might not be representative of the overall
female population.5,23 The present study included random
samples of general populations from different Northern European
countries.The presence of interaction between reproductive factors
(menopause) and BMI is consistent with previous analyses.7,24,25
Further research should focus on intervention because our results
suggest that women have less impairment in respiratory health
during menopause if they commence the menopausal transition
with a normal BMI.
In our study menopause was based on women reporting their
menstrual status26 and use of hormones in a questionnaire.
Menopausal status was defined according to the STRAW
classification,21 with the exception that a cutoff of 6 months or
more for amenorrheawasused insteadof12monthsormorebecause
of the definition of menopause at baseline. Levels of measured
estradiol correspondedwell with expected levels of estradiol among
postmenopausal and nonmenopausal women22 and confirmed that
the definition based on questionnaire data was acceptable. This is
in agreement with literature showing that women report
reproductive datawithhigh reliability.7,13,26-29Althoughmenopause
for clinical purposes is defined retrospectively as the first day of the
last menstruation followed by 12 months without menstruations,21
menopausal status in biological terms is a continuum and any
definition based on categories will have limitations.27 Although
results were very consistent for the early and late postmenopausal
groups, the group in the menopausal transition showed less
consistent findings. This transitional stage is difficult to assess and
needs further investigation with more refined methods for defining
hormonal status.
FIG 3. Change in number of respiratory symptoms according to change in
menopausal status (n 5 2322). The size of each circle is proportional to the
number of persons in each group.
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inflammatory condition of the airways30,31 in which systemic
inflammation is important in the pathophysiology,32 and sex
steroids have an effect on the immune regulation, with
estradiol showing both proinflammatory and anti-inflammatory
properties.30,33-35 The effects of estrogens on eosinophils and
mast cells might be particularly relevant for asthma.36-38
Decreasing estradiol levels because of menopause potentially
reduce protective influences on the lungs and thereby increase
susceptibility to asthma and respiratory symptoms. Because
asthma is a complex disease, it is plausible that more than 1
pathway is responsible for exacerbation or the development of
late-onset asthma.9,39 It is suggested that a sex steroid pathway
might play a distinct role in reaching a threshold that could trigger
a noticeable difference in bronchial reaction.9 Furthermore,
increased systemic inflammation caused by metabolic dysfunc-
tion among postmenopausal women might also contribute to
our findings.40Our study has clear advantages over previous studies
because it is the first population-based longitudinal study in
the field. The external validity is high because it is a
multinational multicentric study; furthermore, the study is
large enough to allow relevant subgroup analysis. Menopausal
status was defined in several categories, and the sample size
made it possible to distinguish between women in the
menopausal transition and women in early and late stages of
postmenopause. Measurements of estradiol levels in a subsam-
ple supported the questionnaire-based definitions of these
menopausal stages. A limitation was that information collected
at baseline did not detail the causes for irregular menstruation.
Therefore women with irregular menstruation at baseline were
excluded, and the longitudinal changes in respiratory health in
women who were in the menopausal transition at baseline
could not be addressed.
Another limitation of the study is the definition of the
outcome variables according to questionnaire data. However,
to elucidate more objective descriptions poses a challenge
because asthma is a heterogeneous condition, airway
obstruction fluctuates, and a gold standard to define asthma
is still to be determined.41-43 In the present analyses we used
2 measures of asthma, one more specific for diagnosed
asthma and another based on asthma symptoms. It cannot
be ruled out that respiratory symptoms might sometimes
reflect respiratory tract infections; however, our approach is
based on common operational definitions reflecting asthma
on a population basis. Questionnaire data concerning
asthma for epidemiologic studies have been validated in other
studies reporting strong positive associations with a clinical
diagnosis of asthma.42,44,45 The sensitivity and specificity of
self-reported asthma are generally high43 and highlight why
questionnaire data for the definition of asthma are widely
used.
In conclusion, the present analysis indicates that there is a
strong and consistent association between change in
menopausal status and risk of new-onset asthma and
respiratory symptoms. The findings should be confirmed in
different populations in future studies. Mechanisms relating
respiratory health to reproductive aging, as well as the
potential effect of modifiable risk factors, such as being
overweight, need to be further investigated. Considering the
projected increase in the number of older adults globally,
reproductive aging and postmenopausal quality of life are
increasingly relevant, and policymakers should consider the
burden of disease and the costs related to menopausal asthma.
Moreover, clinicians should be aware that women might
experience deterioration of respiratory health and have asthma
during menopause.
Dr Jordi Sunyer and Natalia Vilor Tejedor from CREAL in Barcelona
contributed to the respiratory symptoms score. Dr AdrianMcCann contributed
to improve language and grammar.Clinical implications: Health care professionals should be
aware that women are more susceptible to asthma and respira-
tory symptoms when they become menopausal.
TABLE III. Change in number of respiratory symptoms* according to change in menopausal status and covariates (n 5 2322)
Unadjusted Adjusted
Coefficient (95% CI) P value Coefficient (95% CI)y P value
Menopausal status
Nonmenopausal Reference Reference
Menopausal transition§ 20.02 (20.45 to 0.42) .9 0.18 (20.26 to 0.62) .4
Early postmenopausek 0.19 (20.12 to 0.50) .2 0.40 (0.06 to 0.75) .02
Late postmenopause{ 0.29 (20.14 to 0.72) .2 0.69 (0.15 to 1.23) .01
Age 20.02 (20.04 to 0.00) .11 20.04 (20.07 to 20.01) .003
BMI 0.05 (0.02 to 0.07) < .001 0.04 (0.02 to 0.07) < .001
Smoking
Never smoker Reference Reference
Former smoker 0.11 (20.15 to 0.37) .4 0.21 (20.05 to 0.47) .12
Current smoker 0.68 (0.39 to 0.97) < .001 0.64 (0.33 to 0.94) < .001
Physical activity#
>1 h/wk (vigorous) Reference Reference
>1 h/wk (light) 20.01 (20.34 to 0.32) .9 20.04 (20.37 to 0.29) .8
<1 h/wk (vigorous) 0.07 (20.32 to 0.46) .7 0.01 (20.38 to 0.40) 1.0
<1 h/wk (light) 0.56 (0.23 to 0.89) .001 0.39 (0.06 to 0.73) .02
None 0.45 (0.13 to 0.78) .006 0.26 (20.07 to 0.59) .13
Education
University Reference Reference
High school 0.04 (20.21 to 0.28) .8 20.14 (20.39 to 0.11) .3
Primary 0.27 (20.10 to 0.64) .2 0.10 (20.29 to 0.49) .6
Boldface indicates estimates with a P value less than .05 (statistical significance).
*Respiratory symptoms score (0-3) displays the sum of the following 3 questions answered with ‘‘yes’’: ‘‘Have you been breathless while wheezing at any time in the last 12
months?,’’ ‘‘Have you woken up with a feeling of tightness in your chest at any time in the last 12 months?,’’ and ‘‘Have you been woken by an attack of shortness of breath at any
time in the last 12 months?’’
Negative binomial regressions mutually adjusted for all covariates.
Regular menstruation at baseline and follow-up.
§Regular menstruation at baseline and irregular or few menstruations at follow-up (irregular for a few months, 3-9 periods in the last 12 months, no menstruation for <6 months,
1 ovary removed or hysterectomy).
kRegular menstruation at baseline and postmenopause at follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
{Postmenopause at baseline and follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
#Exercise frequency per week * duration per session for either light or heavy intensity (frequency per week * duration 5 numbers of training units per week times their duration
[unit: h/wk]).
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METHODS
Definition of menopausal status
Menopausal status was defined based on criteria of the STRAW clinically
oriented classification,E1 with the exception that amenorrhea for 6 months or
more was used instead of 12 months or more because of the definition of
menopause in the questionnaire at baseline.
At baseline, women answering ‘‘yes’’ (alternatives are ‘‘yes,’’ ‘‘no,’’ and
‘‘don’t know’’) to the question ‘‘Do you have regular periods?’’ were classified
as nonmenopausal. Women answering ‘‘yes’’ (alternatives are ‘‘yes,’’ ‘‘no,’’
and ‘‘don’t know’’) to the question ‘‘Do you have the menopause (six months
or more since your last period)?’’ were classified as menopausal.
At follow-up, women were categorized according to answers given to the
following questions:
1. ‘‘Do you have regular periods?’’ (alternatives ‘‘yes’’; ‘‘no, they have
never been regular’’; ‘‘no they have been irregular for a few months’’;
and ‘‘no, my periods have stopped’’)
2. ‘‘When was your last period? (Please fill in the date of the first day of
your last period or the year if you cannot remember the exact date,
even if you are no longer menstruating)’’
3. ‘‘How many periods have you had in the last 12 months?’’
4. ‘‘If you have had no periods in the last 12 months, what statement best
describes the reason you have not had a period in the last 12 months?’’
(alternatives are ‘‘menopause,’’ ‘‘womb removed,’’ ‘‘ovaries removed,’’
‘‘currently pregnant,’’ ‘‘currently breast-feeding,’’ ‘‘because I have been
taking treatments (eg, hormonal IUD, contraceptive implants,
chemotherapy),’’ and ‘‘other’’)
5. ‘‘Have you ever had a hysterectomy (your womb removed)?’’
(alternatives are ‘‘no’’ and ‘‘yes’’)
6. ‘‘Have you ever had one or both ovaries removed?’’ (alternatives are
‘‘never,’’ ‘‘yes, one ovary,’’ ‘‘yes, two ovaries,’’ and ‘‘don’t know’’)
Nonmenopausal was defined as reporting 10 to 14 periods per year.
Transitional was defined as having reported ‘‘irregular menstruation for a
few months,’’ cessation of menstruation with less than 183 days since the
last period, 3 to 9 periods in the last 12 months, having 1 ovary removed,
and/or reporting a hysterectomy.E2-E5
Menopausal was defined as cessation of menstruation for at least 6
months,E6 more than 182 days since the last period, less than 3 periods in
the last 12 months,E5 or having both ovaries removed.
We defined change in menopausal status according to the categories
describing menopausal status at baseline and follow-up. We classified women
according to change in menopausal status as follows:
1. nonmenopausal: nonmenopausal at both baseline and follow-up
(reference category);
2. transitional: nonmenopausal at baseline and transitional at follow-up;
3. early postmenopausal: nonmenopausal at baseline and menopausal at
follow-up;
4. late postmenopausal: menopausal at both baseline and follow-up.
REFERENCES
E1. Menopause practice: a clinician’s guide. Mayfield Heights (OH): North American
Menopause Society; 2004.
E2. Farquhar CM, Sadler L, Harvey SA, Stewart AW. The association of hysterec-
tomy and menopause: a prospective cohort study. BJOG 2005;112:956-62.
E3. Wilkosz P, Greggains GD, Tanbo TG, Fedorcsak P. Female reproductive decline
is determined by remaining ovarian reserve and age. PLoS One 2014;9:e108343.
E4. Cooper GS, Thorp JM Jr. FSH levels in relation to hysterectomy and to unilateral
oophorectomy. Obstet Gynecol 1999;94:969-72.
E5. Brambilla DJ, McKinlay SM, Johannes CB. Defining the perimenopause for
application in epidemiologic investigations. Am J Epidemiol 1994;140:1091-5.
E6. Real FG, Svanes C, Omenaas ER, Anto JM, Plana E, Jarvis D, et al. Lung
function, respiratory symptoms, and the menopausal transition. J Allergy Clin
Immunol 2008;121:72-80.e3.
J ALLERGY CLIN IMMUNOL
JANUARY 2016
57.e1 TRIEBNER ET AL
TABLE E1. Characteristics of the study population by study center
All Aarhus Reykjavik Bergen Gothenburg Umea Uppsala Tartu
Age (y), median (SD) 54 (5.5) 53 (5.0) 53 (5.5) 52 (5.2) 54 (5.6) 56 (5.6) 55 (5.7) 53 (5.2)
Age of menopause (y), median (SD) 50.2 (5.7) 50.0 (4.6) 50.0 (5.2) 49.5 (4.8) 50.2 (5.0) 51.0 (6.6) 51.2 (5.9) 51.0 (7.9)
BMI (kg/m2), median (SD) 24.7 (4.5) 23.7 (4.8) 25.5 (4.5) 24.4 (3.8) 24.7 (4.5) 25.3 (4.6) 24.6 (4.0) 25.2 (5.1)
Smoking
Never smoker 1090 (47) 179 (42) 111 (40) 145 (38) 137 (46) 186 (48) 172 (55) 160 (65)
Former smoker 829 (36) 167 (39) 125 (45) 147 (38) 109 (37) 134 (35) 110 (35) 37 (15)
Current smoker 403 (17) 77 (18) 43 (15) 92 (24) 50 (17) 64 (17) 28 (9) 49 (20)
Physical activity*
>1 h/wk (vigorous) 895 (39) 164 (39) 105 (38) 189 (49) 105 (35) 165 (43) 108 (35) 59 (24)
>1 h/wk (light) 458 (20) 84 (20) 35 (13) 76 (20) 55 (19) 86 (22) 72 (23) 50 (20)
<1 h/wk (vigorous) 268 (12) 42 (10) 28 (10) 47 (12) 38 (13) 37 (10) 48 (15) 28 (11)
<1 h/wk (light) 325 (14) 70 (17) 25 (9) 31 (8) 46 (16) 57 (15) 35 (11) 61 (25)
None 376 (16) 63 (15) 86 (31) 41 (11) 52 (18) 39 (10) 47 (15) 48 (20)
Education
University 1112 (48) 204 (48) 127 (46) 184 (48) 114 (39) 175 (46) 193 (62) 115 (47)
High school 960 (41) 200 (47) 97 (35) 168 (44) 133 (45) 150 (39) 87 (28) 125 (51)
Primary 250 (11) 19 (4) 55 (20) 32 (8) 49 (17) 59 (15) 30 (10) 6 (2)
Menopausal status at follow-up
Nonmenopausal 435 (19) 94 (22) 44 (16) 88 (23) 50 (17) 43 (11) 64 (21) 52 (21)
Menopausal transition 291 (13) 58 (14) 29 (10) 41 (11) 46 (16) 45 (12) 41 (13) 31 (13)
Early postmenopause§ 1,350 (58) 232 (55) 182 (65) 203 (53) 171 (58) 243 (63) 171 (55) 148 (60)
Late postmenopausek 246 (11) 39 (9) 24 (9) 52 (14) 29 (10) 53 (14) 34 (11) 15 (6)
Symptoms{
Breathless while wheezing 182 (8) 21 (5) 25 (9) 39 (10) 30 (10) 27 (7) 19 (6) 21 (9)
Woken by chest tightness 211 (9) 45 (11) 25 (9) 37 (10) 21 (7) 22 (6) 19 (6) 42 (17)
Woken by shortness of breath 113 (5) 15 (4) 6 (2) 16 (4) 13 (4) 14 (4) 15 (5) 34 (14)
Asthma{
Asthma attack 56 (2) 9 (2) 11 (4) 11 (3) 8 (3) 7 (2) 2 (1) 8 (3)
Asthma medication 99 (4) 13 (3) 13 (5) 25 (7) 16 (5) 12 (3) 10 (3) 10 (4)
New-onset asthma# 109 (5) 16 (4) 16 (6) 30 (8) 16 (5) 12 (3) 9 (3) 10 (4)
Total 2322 423 279 384 296 384 310 246
Values are presented as numbers (percentages), unless otherwise stated.
*Exercise frequency per week * duration per session for either light or vigorous intensity (frequency per week * duration 5 numbers of training units per week times their duration
[unit: h/wk]).
Regular menstruation at baseline and follow-up.
Regular menstruation at baseline and irregular or few menstruations at follow-up (irregular for a few months, 3-9 periods in the last 12 months, no menstruation for <6 months,
1 ovary removed or hysterectomy).
§Regular menstruation at baseline, postmenopause at follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
kPostmenopause at baseline and follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
{In the last 12 months.
#Current use of asthma medication, asthma attack, or both during the last 12 months and no asthma at baseline.
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TABLE E2. Change in number of respiratory symptoms*
according to change in menopausal status for women in
whom new-onset asthma did not develop (n 5 2213)
Coefficient (95% CI)y P value
Menopausal status
Nonmenopausal Reference
Menopausal transition§ 0.07 (20.42 to 0.56) .8
Early postmenopausek 0.30 (20.07 to 0.68) .11
Late postmenopause{ 0.66 (0.05 to 1.28) .03
*Respiratory symptoms score (0-3) displays the sum of the following 3 questions
answered with ‘‘yes’’: ‘‘Have you been breathless while wheezing at any time in the
last 12 months?,’’ ‘‘Have you woken up with a feeling of tightness in your chest at any
time in the last 12 months?,’’ and ‘‘Have you been woken by an attack of shortness of
breath at any time in the last 12 months?’’
Negative binomial regressions adjusted for age, BMI, physical activity, smoking,
education, and center.
Regular menstruation at baseline and follow-up.
§Regular menstruation at baseline and irregular or few menstruations at follow-up
(irregular for a few months, 3-9 periods in the last 12 months, no menstruation for
<6 months, 1 ovary removed or hysterectomy).
kRegular menstruation at baseline and postmenopause at follow-up (<3 periods in the
last 12 months, amenorrhea for >6 months, both ovaries removed).
{Postmenopause at baseline and follow-up (<3 periods in the last 12 months,
amenorrhea for >6 months, both ovaries removed).
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TABLE E3. New-onset asthma according to change in meno-
pausal status for never smokers (n 5 1090)
OR (95% CI)* P value
Menopausal status
Nonmenopausal Reference
Menopausal transition 3.00 (1.00-9.04) .05
Early postmenopause§ 1.73 (0.61-4.91) .3
Late postmenopausek 3.78 (0.77-18.63) .10
OR, Odds ratio.
*Logistic regressions adjusted for age, BMI, physical activity, smoking, education,
and center.
Regular menstruation at baseline and follow-up.
Regular menstruation at baseline and irregular or few menstruations at follow-up
(irregular for a few months, 3-9 periods in the last 12 months, no menstruation for
<6 months, 1 ovary removed or hysterectomy).
§Regular menstruation at baseline and postmenopause at follow-up (<3 periods in the
last 12 months, amenorrhea for >6 months, both ovaries removed).
kPostmenopause at baseline and follow-up (<3 periods in the last 12 months,
amenorrhea for >6 months, both ovaries removed).
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TABLE E4. Respiratory symptoms score* according to change
in menopausal status for never smokers (n 5 1090)
Coefficient (95% CI)y P value
Menopausal status
Nonmenopausal Reference
Menopausal transition§ 20.02 (20.74 to 0.69) .9
Early postmenopausek 0.43 (20.13 to 0.98) .13
Late postmenopause{ 0.56 (20.38 to 1.51) .2
*Respiratory symptoms score (0-3) displays the sum of the following 3 questions
answered with ‘‘yes’’: ‘‘Have you been breathless while wheezing at any time in the
last 12 months?,’’ ‘‘Have you woken up with a feeling of tightness in your chest at any
time in the last 12 months?,’’ and ‘‘Have you been woken by an attack of shortness of
breath at any time in the last 12 months?’’
Negative binomial regressions adjusted for age, BMI, physical activity, smoking,
education, and center.
Regular menstruation at baseline and follow-up.
§Regular menstruation at baseline and irregular or few menstruations at follow-up
(irregular for a few months, 3-9 periods in the last 12 months, no menstruation for
<6 months, 1 ovary removed or hysterectomy).
kRegular menstruation at baseline and postmenopause at follow-up (<3 periods in the
last 12 months, amenorrhea for >6 months, both ovaries removed).
{Postmenopause at baseline and follow-up (<3 periods in the last 12 months,
amenorrhea for >6 months, both ovaries removed).
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TABLE E5. New-onset asthma according to change in menopausal status stratified by BMI (tertiles [n 5 2322])
Lower BMI tertile
(<_23.15 kg/m2 [n 5 774]),
OR (95% CI)*
Medium BMI tertile
(23.15-26.39 kg/m2 [n 5 775]),
OR (95% CI)*
Upper BMI tertile
(>_26.42 kg/m2 [n 5 773]),
OR (95% CI)*
Menopausal status
Nonmenopausal Reference Reference Reference
Menopausal transition 2.00 (0.53-7.49) 1.16 (0.30-4.52) 13.79 (1.59-119.28)
Early postmenopause§{ 1.22 (0.37-3.96) 1.21 (0.42-3.49) 12.79 (1.61-101.94)
Late postmenopausek# 1.71 (0.22-13.42) 1.55 (0.31-7.74) 26.15 (2.62-261.13)
OR, Odds ratio.
*Logistic regressions adjusted for age, BMI, physical activity, smoking, education, and center, including relevant interaction term.
Regular menstruation at baseline and follow-up.
Regular menstruation at baseline and irregular or few menstruations at follow-up (irregular for a few months, 3-9 periods in the last 12 months, no menstruation for <6 months,
1 ovary removed or hysterectomy).
§Regular menstruation at baseline and postmenopause at follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
kPostmenopause at baseline and follow-up (<3 periods in the last 12 months, amenorrhea for >6 months, both ovaries removed).
{Pinteraction 5 .054 for interaction between early postmenopause and BMI as continuous variables for new-onset asthma.
#Pinteraction 5 .047 for interaction between early postmenopause and BMI as continuous variables for new-onset asthma.
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